期刊文献+

多种疾病共存是心力衰竭住院患者在院病死率的独立预测因子 被引量:4

Coexistence of Multiple Disease is an Independent Predictor of In-hospitalized Mortality Patients with Congestive Heart Failure
下载PDF
导出
摘要 目的本项研究主要是调查充血性心力衰竭(congestive heart failure,CHF)住院患者多种疾病共存分布特点,及对CHF患者30天在院病死率的影响。方法 6949名CHF住院患者(男性4344例,女性2605例)按照共存疾病数目分成5组,采用COX比例风险模型比较各组间的共存疾病特点及30天在院病死率。结果 CHF住院患者的主要病因是冠心病(45%)、瓣膜性心脏病(27.5%)和肺心病(9.6%)。年轻人以单病因为主(18~39岁,P<0.001),老年人以多种疾病共存为主(≥80岁,P<0.001)。最常见的单病因是瓣膜性心脏病,最常见的多病因是冠心病伴发高血压、糖尿病。COX风险回归模型显示CHF住院患者的在院病死率随疾病数目的增加而增加(P<0.001)。结论多种疾病共存是预测CHF住院患者在院30天病死率的独立危险因素。 Objective To investigate the major causes,comorbidities and 30-day mortality of congestive heart failure(CHF) in hospitalized patients.Methods All 6949 patients(4344 males,2605 females) of CHF were identified and divided into five groups according to the number of comorbidities.Cox proportional hazards regression was used to examine the association between the number of comorbidities and in-hospital mortality in patients with CHF.Results The major causes of hospitalized patients with CHF were coronary artery disease(45.0%),vavular heart disease(27.5%) and cor Pulmonale(9.6%).A single comorbidity was predominant in younger patients(18-39 years,P0.001),while multiple comorbidities were predominant in the elderly(≥80 years,P0.001).The most common single etiology was valvular heart disease,and the most common triple etiology was hypertension and diabetes mellitus complicated by coronary artery disease.Cox regression analysis showed a higher hospital mortality rate associated with an increased number of comorbidities(P0.001).Conclusion This study demonstrates the coexistence of multiple diseases is an independent predictor of the 30-day mortality of hospitalized patients with CHF.
出处 《医学研究杂志》 2012年第2期130-134,共5页 Journal of Medical Research
关键词 充血性心力衰竭 病因 共病 在院病死率 Congestive heart failure Etiology Comorbidity In-hospital mortality
  • 相关文献

参考文献3

二级参考文献21

  • 1Cleland JG, Clark A. Has the survival of the heart failure population changed? Lessons from trials. Am J Cardiol, 1999,83:112D-119D.
  • 2Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J, 1997,133:703-712.
  • 3Gary R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA, 1995,273:1450-1456.
  • 4Cleland JG, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet, 1998,352:19-28.
  • 5Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure: a request for more accurate classification. Eur Heart J, 1996,17:1390-1403.
  • 6Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest, 1978,73:8-13.
  • 7Jugdutt BI, Khan MI. Effect of prolonged nitrate therapy on left ventricular remodeling after canine myocardial infarction. Circulation, 1994,89:2297-2307.
  • 8Packer M, O′Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in servere chronic heart failure. N Engl J Med, 1996,335:1107-1114.
  • 9Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-Heft III. Circulation, 1997,96:856-863.
  • 10The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet, 1999,353:9-13.

共引文献1437

同被引文献42

  • 1张明园,朱紫青.精神医学[J].中华医学杂志,1995,75(12):725-726. 被引量:7
  • 2张蕙元,周伟.磷酸肌酸早期干预对重度窒息新生儿脑损伤程度的影响[J].中国如幼保健,2008,23(18):2534-2535.
  • 3Yancik R,Ershler W,Satariano W,et al.Report of the national institute on aging task force on comorbidity[J].J Gerontol A Biol Sci Med Sci,2007(3):275-280.
  • 4Boyd CM,Leff B,Wolff JL,et al.Informing clinical practice guideline development and implementation:prevalence of coexisting conditions among adults with coronary heart disease[J].J Am Geriatr Soc,2011(5):797-805.
  • 5Kjeldsen SE,Erdine S,Faesang C,et al.1999 WHO/ISH hypertension guidelines-highlighes&ESH update[J].J Hypertens,2002(1):153-155.
  • 6Folsom AR,Yamagishi K,Hozawa A,et al.Absolute and attributable risks of heart failure incidence in relation to optimal risk factors[J].Cire Heart Fail,2009(2):11-17.
  • 7East MA,Peterson ED,Shaw LK,et al.Racial differences in the outcomes of patients diastolic heart failure[J].Am Heart J,2004(148):151-156.
  • 8Kazuhiko N,Kawasaki M,Kunihiko T.Us efulness of th oracic elect rical bioimpendan ce cardiography:nonin vasive m onit oring of cardiac ou tpu t[J].J Card Fail,2003(9):170.
  • 9Aneja A,Tang WH,Bansilal S,et al.Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide-I in patients with type 2 disabetes[J].J Clin Endocrinol Metab,2003(6):2719-2727.
  • 10van Poelgeest MI,Nijhuis ER.Kwappenberg KM,et al.Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1,E2 and E6 antigens during HPV16-induced cervical infection and neoplasia[J].Int J Cancer,2006(3):675-683.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部